Skip to content
featured-image

Press Release

iSchemaView Introduces Rapid ASPECTS

State-of-the-Art Imaging Solution Provides Automated Scoring to Assess Early Signs of Brain Ischemia Gothenburg, Sweden – May 15, 2018 – Today at the European Stroke Organization Conference, iSchemaView, the leader in automated cerebrovascular imaging analysis, publicly launched RAPID ASPECTS, a digital imaging solution that assists clinicians in assessing early signs of brain ischemia in stroke. RAPID ASPECTS automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score. RAPID ASPECTS is CE-marked for use in Europe. The original Alberta Stroke Program Early CT Score (ASPECTS) is a manual 10-point scoring system that relies on determining subtle changes in non-contrast CT examinations. This has traditionally required the expertise of an experienced neuroradiologist or stroke neurologist. Yet even stroke imaging experts have been shown to display significant scoring variability in most studies using ASPECTS. RAPID ASPECTS automates and standardizes the scoring process to help clinicians more accurately assess early signs of brain ischemia. “In my opinion, using RAPID ASPECTS increases the likelihood of getting a reliable ASPECT score, independent of the individual skills and experience of the clinician. This tool is therefore particularly suitable for primary stroke centers with a smaller number of cases,” said Dr. Benjamin Friedrich, docent and physician in the Department of Diagnostic and Interventional Neuroradiology at the Klinikum rechts der Isar in Munich. “Early and reliable information makes it possible to quickly understand the prognosis of a patient.” “ASPECT scoring plays a critical role in the treatment of brain ischemia leading to stroke and is part of the American Heart Association guidelines for use of endovascular therapy in patients who can be treated within six hours of symptom onset,” said Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of iSchemaView. “RAPID ASPECTS elevates the ASPECT scoring system, by providing clinicians with more reliable and reproducible scores and powerful visualization tools to support treatment decisions". RAPID ASPECTS receives data from standard CT scanners, tilt-corrects the images and identifies the ASPECTS regions. A sliding confidence indicator allows the physician to scrutinize suspicious regions and determine a final score. Moving the confidence slider to the left identifies additional regions that may potentially be involved, while moving the slider to the right removes regions with more subtle differences. In addition, RAPID ASPECTS includes these features: Slice up and down, zoom and window options that enable the clinician to evaluate different regions of interest Manual score adjustment by adding or subtracting regions Return to fully automated score with one click “RAPID ASPECTS is the state-of-the-art offering for consistent, actionable ASPECT scoring,” said Don Listwin, CEO of iSchemaView. “Clinicians who use RAPID ASPECTS are better able to facilitate quick diagnoses and share information with internal care teams or specialty treatment centers for referrals. Whether it’s CTP, CTA, MRI or now ASPECTS, more than four hundred stroke centers worldwide are using RAPID imaging solutions to successfully identify and treat more stroke patients than ever before.” Key Presentations at ESOC iSchemaView cofounder, Dr. Greg Albers, will present at three sessions: “Key Subgroup Analyses From the DEFUSE 3 Study” during the Presidential Symposium on Wednesday, May 16 at 15:00 in Hall C. “Validation of the Clinical/Core Mismatch and Perfusion/Core Mismatch Selection Criteria for Late Window Thrombectomy: Pooled Analysis of DEFUSE 3 And DAWN” during the Reperfusion II session on Thursday, May 17 at 10:40 in Hall K3. Medtronic Care Continuum: Patient Pathway , Thursday, May 17, at 12:45 in Hall K1. Dr. Benjamin Friedrich of the Department of diagnostic and interventional Neuroradiology at the Klinikum rechts der Isar will present a paper on automated ASPECTS scoring software, titled “Software-Based, Automated Calculation of the ASPECT Score In Patients Suffering From Emergent Vessel Occlusions in the Anterior Circulation – Clinical Feasibility And Reliability,” during the Reperfusion Trials session on Friday, May 18 at 09:50 in Hall K2.

featured-image

Press Release

iSchemaView Receives FDA Clearance for Rapid CTA

Leader in Advanced Cerebrovascular Imaging First to Meet the Needs of Large and Small Centers and Hospitals with New CTA Support and 3D Imaging Added to Complete Suite of Rapid Offerings Redwood City, Calif. – May 1, 2018 – iSchemaView, the leader in cerebrovascular imaging analysis, today announced it has received final clearance from the U.S. Food and Drug Administration (FDA) for RAPID CTA, the company’s 3D imaging solution for Computed Tomography Angiography. RAPID CTA is the newest addition to iSchemaView’s industry leading neuroimaging platform — including RAPID CTP and RAPID MRI — which is designed to provide physicians with fast, fully-automated, elegant and easy-to-interpret imaging that facilitates clinical decision making around cerebrovascular disease, such as stroke. In simplest terms, CTA provides visualization of blood vessels in the brain. Using an injectable contrast agent, high-tech X-ray imaging and sophisticated computer analysis, a CT angiogram provides physicians with detailed and accurate images of the vasculature. However, interpreting standard CTA output is a cumbersome timeconsuming process. RAPID CTA automatically provides clear, easy to interpret CTA maps which include a colored overlay to identify brain regions with reduced blood vessel density. The severity of reduction can be readily visualized by a simple, four-color-coded scale. Additionally, a 3D reconstruction of the vasculature allows physicians to rotate the image for optimal viewing of the vessels from multiple angles. All of this in a few minutes. RAPID CTA is a phenomenal tool for all doctors involved in neurovascular emergencies – from the ER doctor making decisions about patient transfer to the neurointerventionalist getting ready for an incoming thrombectomy procedure. “Our goal is to provide healthcare professionals around the world with the most comprehensive and intuitive suite of imaging solutions possible,” said Don Listwin, CEO of iSchemaView. “With new FDA clearance and the release of RAPID CTA, we are making good on that goal. We ensure physicians can take advantage of RAPID’s power whether they choose plain CT, CT Angiography, CT Perfusion or MR diffusion and perfusion. It’s all about offering them the right imaging solution choice, for the right patient at the right time.” In an effort to save valuable diagnosis and treatment time, RAPID CTA also offers remote viewing for physicians in the hospital, at home or on the road. Image maps are immediately available to doctors for review on any desktop or mobile device. RAPID CTA maps provide an intuitive and easy to interpret view of the brain vessels, helping physicians with: Clinical decision making Patient triage Collaboration between community hospitals and specialists Appropriate patient transfers to specialty centers “Many eligible stroke patients with large vessel occlusions must be quickly transferred to a comprehensive stroke center. The new automated RAPID CTA tool makes it easy for community hospitals to quickly identify potential candidates for treatment and for experts at the comprehensive centers to verify that the patient is appropriate for transfer,” said Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of iSchemaView. “With the addition of CTA to RAPID’s FDA indications, hospitals and clinics of all sizes and locations can now use the platform to immediately review images from wherever they are. That’s powerful.”

featured-image

Press Release

iSchemaView Technology RAPIDly Adopted by Over 350 Stroke Centers

RAPID Becoming a New Standard in Advanced Cerebrovascular Imaging Redwood City, Calif. – April 24, 2018 – iSchemaView, the leader in cerebrovascular imaging analysis, today announced accelerating adoption of its platform. As of today over 350 stroke centers are now using RAPID advanced imaging technology to assist physicians in the analysis of brain images using automated tools for CT, CT Perfusion, MR diffusion and perfusion. With over 350 stroke centers now using RAPID around the world, regular daily use at the centers is generating over 50,000 scans a year. With 200 or more systems expected to come online in 2018, scan count is projected to approach 100,000 per year. “It is terrific to see the industry respond so dramatically to recent studies and adopt RAPID so quickly,” said Don Listwin, CEO of iSchemaView. “The most important result is that we are getting our complete imaging solution into as many hospitals as possible for the benefit of substantially more addressable patients. We want to put an end to time constrained ‘wait and see’ stroke outcomes, and put RAPID to work for all.” Under IRB approval, iSchemaView’s RAPID platform was recently used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies helped change the AHA stroke guidelines to include CT Perfusion and MR perfusion. The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well. "Now there's the potential to treat based on best evidence not just best guess, that’s what RAPID’s perfusion platform affords,” said Christian Ramsey, MD, Neurosurgeon and Surgical Director of Stroke at Baptist Health System. “More patients with more treatment options offers the potential for successful outcomes in patients with historically terrible prognoses.” Today, Gregory W. Albers MD, Stanford University Neurologist and cofounder of iSchemaView, will also be presenting Expanding the Time Window for Thrombectomy: Results of the DEFUSE 3 Study at the Annual Meeting of The American Academy of Neurology in Los Angeles.

featured-image

Press Release

iSchemaView Names Don Listwin as CEO

Silicon Valley Leader Joins Innovator in Cerebrovascular Imaging to Revolutionize Stroke Care Redwood City, Calif. – April 16, 2018 – iSchemaView, the leader in cerebrovascular imaging analysis, today announced that former Cisco and Openwave Systems executive, Don Listwin, has joined the company as Chief Executive Officer (CEO). Listwin comes to iSchemaView with over 30 years of technology management experience, helping dramatically grow both large and emerging brands. “Don stands out as a highly respected leader with an incredible track record of success. He will ensure that iSchemaView capitalizes on its leadership position as the company that provides automated software solutions that aid in the diagnosis of cerebrovascular disease, and are used by many of the world’s leading stroke centers as they work to identify and successfully treat more patients than ever before,” said Gregory W. Albers MD, Stanford University Neurologist and cofounder of iSchemaView. “RAPID is the only imaging software solution used in the studies that selected patients for stroke treatment in the expanded window between six and twenty-four hours. Don will help us not just grow quickly, but also intelligently, as we meet the large demand for clinically proven imaging software in the US and around the world.” iSchemaView’s RAPID platform assists physicians in the analysis of brain images using automated tools for CT, CT Perfusion and MR diffusion and perfusion. Under IRB approval, RAPID was recently used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies have changed the AHA stroke guidelines to include CT Perfusion and MR perfusion. The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well. “Greg and his co-founder Doctor Roland Bammer, innovators in the treatment of stroke, had a mission to eliminate the long-term dogma that stroke was untreatable after three to six hours,” said Don Listwin, CEO of iSchemaView. “With an intuitive but novel approach to brain imaging they are achieving their goal. And with a world of healthcare administrators and clinicians interested in taking advantage of new guidelines I look forward to helping iSchemaView achieve business success and more importantly to help physicians effectively diagnose and treat many more afflicted patients than previously thought possible.” Don Listwin spent a decade at Cisco Systems, where he served as executive vice president. During his tenure at Cisco, Don built several multi-billion-dollar lines of business, including the company’s Service Provider line of business that underpins much of today’s global Internet infrastructure. More recently, Listwin served as chief executive officer of both Sana Security and Openwave Systems. In addition, Don founded and holds the role of chief executive officer of the Canary Foundation, a non-profit research organization focused on the early detection of cancer. He also serves as a director on the boards of AwareX, Calix, D-wave, POET Technologies, iSchemaView, Robin Systems and Teradici. Previously, he also served on the boards or was an advisor to JDS Uniphase, PLUMgrid, Redback Networks, E-TEK Dynamics, the Cellular Telecommunications & Internet Association (CTIA) and the Business Development Bank of Canada (BDC). Listwin received a BSEE from the University of Saskatchewan, He is also a consulting professor in the School of Medicine at Stanford University